photo of

Details

Role Group Leader / Senior Research Fellow
Research area Genomic Medicine

Contact

Available for student supervision
Associate Professor David Godler is a Principal Fellow at the University of Melbourne, group leader of the Diagnosis and Development Laboratory at the Murdoch Children’s Research Institute (MCRI) and is on the executive of the Genomic Screening Consortium for Australian Newborns (GenSCAN). He has completed his PhD in 2007 at the Department of Medicine, Monash University in genetics and immunology, then undertook post-doctoral studies on epigenetic disorders associated with chromosomal abnormalities and developmental delay in the laboratory of Professor Andy Choo. He was later appointed senior postdoctoral fellow at the Victorian Clinical Genetics Services (VCGS) and MCRI, demonstrating strong evidence of innovation and research translation. To date he has been named as an inventor on 6 patent families (with more than 40 patent filings), including 16 granted patents, related to technologies developed for different diagnostic and screening applications, He has 59 publications (41 as 1st or last author) in such quality journals as Genetics in Medicine (X4), Clinical Chemistry (X3), Neurology (X2), JAMA Neurology (X1), JAMA Network Open (X1) and Molecular Autism (X1). In 2018, he was awarded a Next Generation Clinical Researchers Program - Career Development Fellowship, focusing on improved diagnosis, natural history studies and clinical trials for neurodevelopmental disorders associated with intellectual disability and autism. In 2020 he established and currently leads the Australian first Chromosome 15 imprinting Disorders national biobank. In 2022 he was awarded a 5-year program funding from the Genomics Health Futures Mission, the Medical Research Future Fund. This program aims to assess benefits of extended epi-genomic newborn screening workflow developed by his group on 100,000 infants recruited into a $55 million funded whole-of-state birth cohort called Generation Victoria (https://www.genv.org.au/for-researchers/current-genv-collaborations/).
Associate Professor David Godler is a Principal Fellow at the University of Melbourne, group leader of the Diagnosis and Development Laboratory at the Murdoch Children’s Research Institute (MCRI) and is on the executive of the Genomic Screening...
Associate Professor David Godler is a Principal Fellow at the University of Melbourne, group leader of the Diagnosis and Development Laboratory at the Murdoch Children’s Research Institute (MCRI) and is on the executive of the Genomic Screening Consortium for Australian Newborns (GenSCAN). He has completed his PhD in 2007 at the Department of Medicine, Monash University in genetics and immunology, then undertook post-doctoral studies on epigenetic disorders associated with chromosomal abnormalities and developmental delay in the laboratory of Professor Andy Choo. He was later appointed senior postdoctoral fellow at the Victorian Clinical Genetics Services (VCGS) and MCRI, demonstrating strong evidence of innovation and research translation. To date he has been named as an inventor on 6 patent families (with more than 40 patent filings), including 16 granted patents, related to technologies developed for different diagnostic and screening applications, He has 59 publications (41 as 1st or last author) in such quality journals as Genetics in Medicine (X4), Clinical Chemistry (X3), Neurology (X2), JAMA Neurology (X1), JAMA Network Open (X1) and Molecular Autism (X1). In 2018, he was awarded a Next Generation Clinical Researchers Program - Career Development Fellowship, focusing on improved diagnosis, natural history studies and clinical trials for neurodevelopmental disorders associated with intellectual disability and autism. In 2020 he established and currently leads the Australian first Chromosome 15 imprinting Disorders national biobank. In 2022 he was awarded a 5-year program funding from the Genomics Health Futures Mission, the Medical Research Future Fund. This program aims to assess benefits of extended epi-genomic newborn screening workflow developed by his group on 100,000 infants recruited into a $55 million funded whole-of-state birth cohort called Generation Victoria (https://www.genv.org.au/for-researchers/current-genv-collaborations/).

Top Publications

  • Godler, DE, Christodoulou, J, Bruno, D, Li, X, Inaba, Y, Bui, QM, Francis, D, Elliot, J, Wotton, T, Cohen, J, et al. The use of droplet digital PCR and high resolution melt for detection of low level mosaicism. Pathology 50: s30 2018
    view publication
  • Kraan, CM, Cornish, KM, Bui, QM, Li, X, Slater, HR, Godler, DE. β-glucuronidase use as a single internal control gene may confound analysis in FMR1 mRNA toxicity studies.. PLoS One 13(2) : e0192151 2018
    view publication
  • Kraan, C, Godler, D, Bui, M, Cornish, K. Methylation of the novel 3’ epigenetic FMR1 boundary is associated with loss of postural control in female FMR1 premutation carriers. 2017
    view publication
  • Shelton, AL, Cornish, KM, Godler, D, Bui, QM, Kolbe, S, Fielding, J. White matter microstructure, cognition, and molecular markers in fragile X premutation females.. Neurology 88(22) : 2080 -2088 2017
    view publication
  • Hocking, DR, Birch, RC, Bui, QM, Menant, JC, Lord, SR, Georgiou-Karistianis, N, Godler, DE, Wen, W, Hackett, A, Rogers, C, et al. Cerebellar volume mediates the relationship between FMR1 mRNA levels and voluntary step initiation in males with the premutation.. Neurobiol Aging 50: 5 -12 2017
    view publication

Page 9 of 15